Filtros de búsqueda

Lista de obras de Timothy Cloughesy

18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

artículo científico publicado en 2018

18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy

artículo científico publicado en 2006

18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab

artículo científico publicado en 2012

18F-FDOPA kinetics in brain tumors

artículo científico publicado en 2007

18F-fluorothymidine kinetics of malignant brain tumors

artículo científico publicado en 2007

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

artículo científico publicado en 2015

3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab

artículo científico publicado en 2011

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

artículo científico publicado en 2006

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

artículo científico publicado en 2008

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas

artículo científico publicado en 2012

A gene expression signature predicts recurrence-free survival in meningioma.

artículo científico publicado en 2018

A novel bicompartmental mathematical model of glioblastoma multiforme

artículo científico publicado en 2014

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

scientific article published on 20 May 2020

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

artículo científico publicado en 2006

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

artículo científico publicado en 2009

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma

artículo científico publicado en 2010

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma ⬇️

artículo científico publicado el 4 de febrero de 2011

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

artículo científico publicado en 2009

A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.

artículo científico publicado en 2002

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

article by Timothy F. Cloughesy et al published 20 May 2008 in Journal of Clinical Oncology

A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma

artículo científico publicado en 2004

A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

scientific article published on 17 December 2019

A tool for improving the longitudinal imaging characterization for neuro-oncology cases.

artículo científico publicado en 2008

ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION

ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION.

artículo científico publicado en 2017

ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS

artículo científico publicado en 2018

ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)

ACTR-83. BEVACIZUMAB FOR RADIATION-INDUCED PSEUDOPROGRESSION IN ADULT SUPRASELLAR PILOCYTIC ASTROCYTOMA

artículo científico publicado en 2017

ACTR-89. KARNOFSKY PERFORMANCE STATUS AND STEROID USE IN PHASE II TRIAL OF BEVACIZUMAB AND TEMOZOLOMIDE FOR UPFRONT TREATMENT OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas

artículo científico publicado en 2010

AT-02INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584)

AT-17RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA

ATIM-01. A PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RE-IRRADIATION IN ADULT SUBJECTS WITH TRANSFORMED MUTANT GLIOBLASTOMA

artículo científico publicado en 2017

ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT

ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL

ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM)

artículo científico publicado en 2017

ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE

ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

ATIM-25. IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL

ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA

ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA

ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS

artículo científico publicado en 2017

ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA.

artículo científico publicado en 2015

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

artículo científico publicado en 2011

Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

artículo científico publicado en 2002

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

artículo científico publicado en 2017

Adult Glioblastoma

artículo científico publicado en 2017

Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI.

artículo científico publicado en 2014

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway

artículo científico publicado en 2011

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers

artículo científico publicado en 2016

Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

artículo científico publicado en 2006

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo

artículo científico publicado en 2003

Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas

artículo científico publicado en 2011

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

artículo científico publicado en 2012

Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

artículo científico publicado en 2011

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies

artículo científico publicado en 2013

Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma.

artículo científico publicado en 2014

Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors

artículo científico publicado en 2014

Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T

artículo científico publicado en 2019

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping.

artículo científico publicado en 2015

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma

scientific article published on 20 July 2018

Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells

artículo científico publicado en 2011

BI-10pH-WEIGHTED MRI IN HUMAN GLIOMAS.

artículo científico publicado en 2014

BI-22CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

artículo científico publicado en 2016

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma

artículo científico publicado en 2012

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

scientific article published on April 2009

Bevacizumab as first-line therapy for glioblastoma

artículo científico publicado en 2012

Bevacizumab for newly diagnosed glioblastoma

artículo científico publicado en 2014

Bevacizumab for recurrent ependymoma.

artículo científico publicado en 2009

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

artículo científico publicado en 2014

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy

artículo científico publicado en 2016

Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2016

Biomarkers in NOA-04: another piece to the puzzle

artículo científico publicado en 2016

Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.

artículo científico publicado en 2015

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

artículo científico publicado en 2014

Brain tumor treatment: chemotherapy and other new developments

artículo científico publicado en 2004

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

scientific article published on 04 February 2019

C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.

artículo científico publicado en 2014

CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143.

artículo científico publicado en 2015

CLIN-NEURO/MEDICAL ONCOLOGY

Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2011

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

artículo científico publicado en 2011

Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids

artículo científico publicado en 2016

Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation

artículo científico publicado en 2010

Clinical trial end points for high-grade glioma: the evolving landscape.

scientific article published on 09 February 2011

Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome

artículo científico publicado en 2013

Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas

artículo científico publicado en 2012

Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients

artículo científico publicado en 2013

Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

artículo científico publicado en 2013

Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas

artículo científico publicado en 2020

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

artículo científico publicado en 2015

Considerations for uniform and accurate biospecimen labelling in a biorepository and research environment ⬇️

artículo científico publicado el 7 de enero de 2011

Content based image retrieval for MR image studies of brain tumors

artículo científico publicado en 2006

Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma

artículo científico publicado en 2016

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

artículo científico publicado en 2018

Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas

artículo científico publicado en 2010

Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

scientific article published on 08 August 2018

Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study ⬇️

artículo científico publicado el 8 de diciembre de 2010

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

artículo científico publicado en 2013

Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.

artículo científico publicado en 2008

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma

artículo científico publicado en 2017

D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation.

artículo científico publicado en 2018

DDEL-07INTRAVENOUS TOCA 511 DELIVERY LEADS TO VIRAL DNA IN RESECTED HGG.

artículo científico publicado en 2015

DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES - PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL.

artículo científico publicado en 2015

DDIS-08. DEVELOPMENT OF BRAIN-PENETRANT EGFR INHIBITORS FOR GLIOBLASTOMA

DNA-microarray analysis of brain cancer: molecular classification for therapy

artículo científico publicado en 2004

Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma

artículo científico publicado en 2020

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

artículo científico publicado en 2014

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

artículo científico publicado en 2005

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data

artículo científico publicado en 2019

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation

artículo científico publicado en 2012

Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.

artículo científico publicado en 2017

Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors

artículo científico publicado en 2020

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

artículo científico publicado en 2020

Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples

artículo científico publicado en 2008

Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival.

artículo científico publicado en 2012

Differential induction of glioblastoma migration and growth by two forms of pleiotrophin

artículo científico publicado en 2005

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

artículo científico publicado en 2012

Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma

artículo científico publicado en 2015

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.

artículo científico publicado en 2017

Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement

artículo científico publicado en 2020

Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden

artículo científico publicado en 2020

Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma

artículo científico publicado en 2011

Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric

artículo científico publicado en 2013

Distinct transcription profiles of primary and secondary glioblastoma subgroups.

artículo científico publicado en 2006

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

artículo científico publicado en 2016

Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC.

artículo científico publicado en 2018

EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.

artículo científico publicado en 2004

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling

artículo científico publicado en 2015

EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer

artículo científico publicado en 2013

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

artículo científico publicado en 2009

EPIG-11THE IMPLICATION OF CpG island AND SPINT2 HYPERMETHYLATION IN BOTH IDH1 WILD-TYPE AND MUTANT ADULT DIFFUSE GLIOMAS.

artículo científico publicado en 2015

ET-53IPILIMUMAB FOR RECURRENT GLIOBLASTOMA (GBM).

artículo científico publicado en 2014

EXTH-67. TG02, A BRAIN-PENETRANT MULTI-CDK INHIBITOR, POTENTLY SUPPRESSES MYC-DRIVEN GLIOBLASTOMA

artículo científico publicado en 2017

Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.

artículo científico publicado en 2017

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial

artículo científico publicado en 2020

Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma

artículo científico publicado en 2016

Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy

artículo científico publicado en 2020

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.

artículo científico publicado en 2014

Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis.

artículo científico publicado en 2013

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

artículo científico publicado en 2016

Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma

artículo científico publicado en 2017

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

artículo científico publicado en 2011

Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation

artículo científico publicado en 2018

FDA accelerated approval benefits glioblastoma ⬇️

artículo científico publicado el 1 de diciembre de 2010

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

artículo científico publicado en 2018

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

scientific article published on 14 January 2020

Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma

artículo científico publicado en 2012

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients

artículo científico publicado en 2009

GENE-41. EPIGENETIC DOWN-REGULATION OF THE METALLOTHIONEIN FAMILY IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS

artículo científico publicado en 2017

GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE.

artículo científico publicado en 2015

Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age

artículo científico publicado en 2008

Gene expression profiling identifies molecular subtypes of gliomas

artículo científico publicado en 2003

Gene expression profiling of gliomas strongly predicts survival

artículo científico publicado en 2004

Genomic landscape of meningiomas.

artículo científico publicado en 2009

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

scientific article published on 24 April 2020

Glioblastoma therapy in the elderly: one age does not fit all.

artículo científico publicado en 2012

Glioblastoma: from molecular pathology to targeted treatment

artículo científico

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance

artículo científico publicado en 2015

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2011

Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine

artículo científico publicado en 2017

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma

artículo científico publicado en 2015

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma

artículo científico publicado en 2015

High order diffusion tensor imaging in human glioblastoma.

artículo científico publicado en 2011

Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study

artículo científico publicado en 2020

Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.

artículo científico publicado en 2016

Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2014

IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143.

artículo científico publicado en 2015

IMCT-04TOCA 5: PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 WITH TOCA FC VERSUS STANDARD OF CARE IN PATIENTS UNDERGOING PLANNED RESECTION FOR RECURRENT HIGH GRADE GLIOMA (NCT02414165).

artículo científico publicado en 2015

IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS.

artículo científico publicado en 2015

IMMU-28. HIGH-DIMENSIONAL SINGLE CELL CHARACTERIZATION OF THE SYSTEMIC INFLUENCE OF NEOADJUVANT PD-1 BLOCKADE IN PATIENTS WITH RECURRENT GLIOBLASTOMA

IT-05ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION

artículo científico publicado en 2014

Identification of molecular subtypes of glioblastoma by gene expression profiling

artículo científico publicado en 2003

Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.

artículo científico publicado en 2012

Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images

artículo científico publicado en 2013

Imaging biomarkers for antiangiogenic therapy in malignant gliomas

artículo científico publicado en 2013

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

artículo científico publicado en 2005

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

artículo científico publicado en 2017

Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective

artículo científico publicado en 2012

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium

artículo científico publicado en 2001

Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange.

artículo científico publicado en 2016

Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging

artículo científico publicado en 2017

Improving B Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation

artículo científico publicado en 2018

In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays

artículo científico publicado en 2009

Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma.

artículo científico publicado en 2017

Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab

artículo científico publicado en 2020

Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry

artículo científico publicado en 2013

Initial treatment patterns over time for anaplastic oligodendroglial tumors

artículo científico publicado en 2012

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

artículo científico publicado en 2011

Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas

artículo científico publicado en 1999

Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow

artículo científico publicado el 1 de noviembre de 1997

Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery

artículo científico publicado en 2001

Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma

artículo científico publicado en 1999

Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

artículo científico publicado en 2002

Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?

artículo científico publicado en 2018

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

artículo científico publicado en 2011

It is time to include patients with brain tumors in phase I trials in oncology

artículo científico publicado en 2011

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma

artículo científico publicado en 2020

Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma

artículo científico publicado en 2010

Large-scale assessment of the gliomasphere model system

artículo científico publicado en 2016

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors

scientific article published on 01 September 2019

Lipid Droplets Maintain Energy Homeostasis and Glioblastoma Growth via Autophagic Release of Stored Fatty Acids

artículo científico publicado en 2020

Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients

artículo científico publicado en 2018

Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage.

artículo científico publicado en 2013

MEDICAL AND NEURO-ONCOLOGY

artículo científico publicado en 2011

MR imaging correlates of survival in patients with high-grade gliomas

artículo científico publicado en 2005

MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting

artículo científico publicado en 2020

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

artículo científico publicado en 2006

MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab.

artículo científico publicado en 2015

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

artículo científico publicado en 2006

Mapping therapeutic response in a patient with malignant glioma

artículo científico publicado en 2001

Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells

artículo científico publicado en 2008

Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study

artículo científico publicado en 2020

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM

scientific article published on 03 July 2019

Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI

scientific article published on 04 May 2019

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

artículo científico publicado en 2017

Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy

artículo científico publicado en 2003

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

artículo científico publicado en 2005

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors

artículo científico publicado en 2009

Monitoring carotid test occlusions with continuous EEG and clinical examination.

artículo científico publicado en 1993

Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma

scientific article published on 31 May 2018

Multi-parametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in patients with recurrent high-grade glioma

scientific article published on 08 April 2020

Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas

scientific article published on 14 September 2020

NC-01ATTENTIONAL AND LANGUAGE FUNCTIONING IN ADULT PATIENTS WITH GLIOMA: A VOXEL-BASED LESION-SYMPTOM MAPPING STUDY.

artículo científico publicado en 2014

NCMP-01. SEIZURE CONTROL AFTER INITIAL PRESENTATION IN IDH MUTATED GLIOMA PATIENTS

NI-20ADC HISTOGRAM ANALYSIS FOLLOWING RADIOTHERAPY PREDICTS RESPONSE TO ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GBM.

artículo científico publicado en 2014

NI-21CONTRAST ENHANCED T1 SUBTRACTION MAPS IMPROVE DETECTION OF RESIDUAL TUMOR FOLLOWING RESECTION, REDUCES MEASUREMENT VARIABILITY, AND PREDICTS SURVIVAL AFTER ANTI-ANGIOGENIC THERAPY IN GLIOBLASTOMA.

artículo científico publicado en 2014

NI-22NON-ENHANCING TUMOR RESPONSE USING QUANTITATIVE T2 MAPS PREDICTS SURVIVAL IN GLIOBLASTOMA TREATED WITH BEVACIZUMAB.

artículo científico publicado en 2014

NI-32ENHANCING TUMOR RESPONSE USING QUANTITATIVE VOLUMETRY FROM T1 SUBTRACTION MAPS IN MALIGNANT GLIOMA TREATED WITH DENDRITIC CELL VACCINATION.

artículo científico publicado en 2014

NI-36VALIDATION OF RANO CRITERIA: CONTRIBUTION OF T2/FLAIR ASSESSMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB.

artículo científico publicado en 2014

NI-54HYPERVASCULAR VOLUME ESTIMATED BY COMPARISON TO A LARGE-SCALE CEREBRAL BLOOD VOLUME (CBV) RADIOGRAPHIC ATLAS PREDICTS SURVIVAL IN RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB.

artículo científico publicado en 2014

NI-55PARAMETRIC MAPS OF CONTRAST AGENT DIFFUSION USING A NOVEL DIFFUSION-PERFUSION MODEL APPLIED TO DCE-MRI CAN DIFFERENTIATE NON-ENHANCING TUMOR FROM EDEMA IN HUMAN GLIOBLASTOMA.

artículo científico publicado en 2014

NI-68F-FDOPA PET IN TREATED LOW-GRADE GLIOMAS WITH NON-ENHANCING T2 CHANGES ON MRI IS PROGNOSTIC OF TUMOR PROGRESSION AND OVERALL SURVIVAL

artículo científico publicado en 2014

NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE

artículo científico publicado en 2017

NIMG-08. EVALUATING THE APPLICABILITY OF TUMOR PROBABILITY MAPS AS A RESOURCE FOR IMPROVED BRAIN TUMOR SEGMENTATION

NIMG-15. DIFFERENTIATION OF IDH1 MUTANT AND WILD TYPE GLIOMAS USING pH- AND OXYGEN-SENSITIVE MOLECULAR MRI

NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717).

artículo científico publicado en 2015

NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143.

artículo científico publicado en 2015

NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143).

artículo científico publicado en 2015

NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI).

artículo científico publicado en 2015

NIMG-25IMPROVED LEAKAGE CORRECTION FOR DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI ESTIMATES OF RELATIVE CEREBRAL BLOOD VOLUME (rCBV) IN HIGH-GRADE GLIOMAS BY ACCOUNTING FOR BIDIRECTIONAL CONTRAST AGENT EXCHANGE.

artículo científico publicado en 2015

NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI

NIMG-50. VOLUMETRIC ANALYSIS OF IDH-MUTANT LOW-GRADE GLIOMA: A NATURAL HISTORY STUDY OF TUMOR GROWTH RATES BEFORE AND AFTER TREATMENT

NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS

NIMG-57QUANTITATION OF 18F-DOPA UPTAKE ON PET PREDICTS TUMOR GRADE WITH HIGH SENSITIVITY AND SPECIFICITY IN NEWLY-DIAGNOSED GLIOMA: UCLA EXPERIENCE.

artículo científico publicado en 2015

NIMG-59. VALIDATION OF QUANTITATIVE VESSEL SIZE IMAGING (VSI) IN HUMAN GLIOMAS USING IMAGE-GUIDED STEREOTACTIC BIOPSIES

artículo científico publicado en 2018

NIMG-84. TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

article

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2011

Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.

artículo científico publicado en 2008

Neurosphere formation is an independent predictor of clinical outcome in malignant glioma

artículo científico publicado en 2009

New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target? ⬇️

artículo científico publicado el 1 de enero de 2011

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.

artículo científico publicado en 2017

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

artículo científico publicado en 2011

Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma.

scientific article published on 07 December 2013

Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2011

Novel brainstem syndrome associated with prostate carcinoma

scientific article published on 01 December 1993

Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging

artículo científico publicado en 2002

NovoTTF: where to go from here?

artículo científico publicado en 2017

ONGOING CLINICAL TRIALS

article

OS09.6 Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial.

artículo científico publicado en 2017

Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling

scientific article published on 11 July 2019

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance

artículo científico publicado en 2011

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

artículo científico publicado en 2015

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.

artículo científico publicado en 2012

P01.032 Associations of anticoagulant use with outcome in newly diagnosed glioblastoma ⬇️

PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION

artículo científico publicado en 2018

PATH-17. CORRELATION OF COMMERCIALLY-AVAILABLE QUANTITATIVE (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) METHYLATION SCORES AND OVERALL GBM PATIENT SURVIVAL

PATH-35. MAINTENANCE OF EGFR ABNORMALITIES OVER TIME AND COMPARISON OF MOLECULAR METHODOLOGIES IN GLIOBLASTOMA (GBM)

PCSM-09PSYCHOSOCIAL AND SYMPTOMATIC SCREENING AMONG PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMORS.

artículo científico publicado en 2015

PD-1 blockade enhances the vaccination-induced immune response in glioma

artículo científico publicado en 2016

PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma

artículo científico publicado en 2013

PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors

artículo científico publicado en 2012

PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM.

artículo científico publicado en 2014

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies

artículo científico publicado en 2013

Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth

artículo científico publicado en 2015

Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas

artículo científico publicado en 2014

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

artículo científico publicado en 2015

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

artículo científico publicado en 2019

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

artículo científico publicado en 2011

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas

artículo científico publicado en 2017

Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

artículo científico publicado en 2012

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

artículo científico publicado en 2007

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

artículo científico publicado en 2011

Pharmacological blood-brain barrier modification for selective drug delivery

artículo científico publicado en 1995

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas

artículo científico publicado en 2015

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

artículo científico publicado en 2004

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

artículo científico publicado en 2016

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

scientific article published on 06 January 2018

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

artículo científico publicado en 2017

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

artículo científico publicado en 2012

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

artículo científico publicado en 2015

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

artículo científico publicado en 2012

Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.

artículo científico publicado en 2016

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

artículo científico publicado en 2017

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study

artículo científico publicado en 2007

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

artículo científico publicado en 2012

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas

artículo científico publicado en 2017

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

artículo científico publicado en 2005

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

artículo científico publicado en 2014

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

artículo científico publicado en 2006

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02

scientific article published on 01 January 2020

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

artículo científico publicado en 2012

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

artículo científico publicado en 2004

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

artículo científico publicado en 2003

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

artículo científico publicado en 2005

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

artículo científico publicado en 2011

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

artículo científico publicado en 2010

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

artículo científico publicado en 2017

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

artículo científico publicado en 2017

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study

artículo científico publicado en 2004

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

artículo científico publicado en 2009

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

artículo científico publicado en 2006

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

artículo científico publicado en 2009

Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study

artículo científico publicado en 2007

Platform trials arrive on time for glioblastoma

artículo científico publicado en 2018

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

artículo científico publicado en 2018

Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma

artículo científico publicado en 2013

Predicting major depression in brain tumor patients

artículo científico publicado en 2002

Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach.

artículo científico publicado en 2010

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

artículo científico publicado en 2007

Prediction of neurocognitive outcome in adult brain tumor patients

scientific article published on 01 March 2004

Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma

artículo científico publicado en 2013

Primary glioblastomas express mesenchymal stem-like properties

artículo científico publicado en 2006

Prioritization schema for immunotherapy clinical trials in glioblastoma

scientific article published on 18 February 2016

Probabilistic radiographic atlas of glioblastoma phenotypes.

artículo científico publicado en 2012

Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model

artículo científico publicado en 2009

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

artículo científico publicado en 2008

Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen

artículo científico publicado el 1 de octubre de 1997

Pros and cons of current brain tumor imaging

artículo científico publicado en 2014

Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.

artículo científico publicado en 2017

Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence.

artículo científico publicado en 2013

QL-04FACTORS ASSOCIATED WITH SUICIDAL IDEATION IN CLINICALLY DISTRESSED ADULT GLIOMA PATIENTS.

artículo científico publicado en 2014

QL-05SELF-REPORTED COGNITIVE DIFFICULTIES AND ASSOCIATED MEDICAL CHARACTERISTICS IN PATIENTS WITH ADULT-ONSET GLIOMA.

artículo científico publicado en 2014

Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI

artículo científico publicado en 2015

Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2011

Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy

artículo científico publicado en 2012

Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab

artículo científico publicado en 2011

RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA

Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma

artículo científico publicado en 2015

Radiographic Read Paradigms and the Roles of the Central Imaging Laboratory in Neuro-Oncology Clinical Trials

artículo científico publicado en 2020

Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio

artículo científico publicado en 2017

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

artículo científico publicado en 2008

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA

artículo científico publicado en 2016

Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas

scientific article published on 24 January 2020

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

artículo científico publicado en 2009

Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial

artículo científico publicado en 2013

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors

artículo científico publicado en 2014

Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors

artículo científico publicado en 2012

Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas

artículo científico publicado en 2015

Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis

artículo científico publicado en 2008

Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.

artículo científico publicado en 2007

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma

artículo científico publicado en 2012

Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma.

artículo científico publicado en 2000

Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas

artículo científico publicado en 2020

Reply to B. Freidlin et al.

artículo científico publicado en 2013

Reply to F. Felix et al and M.F. Fay et al.

artículo científico publicado en 2016

Reply to T.J. Kruser et al.

artículo científico publicado en 2016

Reply to comment on: 'Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach'.

artículo científico publicado en 2016

Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study

artículo científico publicado en 2017

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

artículo científico publicado en 2014

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab ⬇️

artículo científico publicado el 17 de noviembre de 2010

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

artículo científico publicado en 2013

Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression

scientific article published on 11 February 2013

Response to Weltman and Fleury Malheiros, re Lassman et al.

artículo científico publicado en 2012

Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies

artículo científico publicado en 2012

Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.

artículo científico publicado en 2015

Robustness of gene expression profiling in glioma specimen samplings and derived cell lines.

artículo científico publicado en 2005

Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases.

artículo científico publicado en 2010

SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA.

artículo científico publicado en 2017

SP-02PATTERNS OF END-OF-LIFE CARE FOR PATIENTS WITH GLIOBLASTOMA

SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation

scientific article published on 05 March 2019

SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION.

artículo científico publicado en 2015

Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study

scientific article published on 17 December 2019

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

artículo científico publicado en 2010

Safety of anticoagulation use and bevacizumab in patients with glioma

artículo científico publicado en 2008

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII

artículo científico publicado en 2019

Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy

artículo científico publicado en 2014

Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T.

artículo científico publicado en 2016

Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI).

artículo científico publicado en 2018

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

artículo científico publicado en 2016

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies

artículo científico publicado en 2009

Somatostatin Receptor Ligand Therapy-A Potential Therapy for Neurocytoma

scientific article published on 01 June 2019

Standards of care for treatment of recurrent glioblastoma--are we there yet?

artículo científico publicado en 2012

Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone

artículo científico publicado en 2009

Striking the balance between PTEN and PDK1: it all depends on the cell context

scientific article published on August 2009

TMOD-03. GLIOMAPDOX: A MOLECULARLY DIVERSE LIBRARY OF DIRECT-FROM-PATIENT ORTHOTOPIC GLIOMA XENOGRAFTS RECAPITULATES INTRATUMOR HETEROGENEITY

artículo científico publicado en 2018

Targeted molecular therapy of GBM.

artículo científico publicado en 2003

Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience

artículo científico publicado en 2020

Targeted therapy for malignant glioma patients: lessons learned and the road ahead

artículo científico publicado en 2009

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.

artículo científico publicado en 2013

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

artículo científico publicado en 2009

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

artículo científico publicado en 2015

The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity

artículo científico publicado en 2008

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide

artículo científico publicado en 2015

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

artículo científico publicado en 2017

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

artículo científico publicado en 2018

The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma

scientific article published on 01 May 2020

The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma

artículo científico publicado en 2011

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas

artículo científico publicado en 2013

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients

scientific article published on 01 December 2019

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

artículo científico publicado en 2010

The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings

artículo científico publicado en 2014

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

scientific journal article

Time course of imaging changes of GBM during extended bevacizumab treatment

artículo científico publicado en 2008

Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas.

artículo científico publicado en 2017

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs

artículo científico publicado en 2019

Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room

artículo científico publicado en 1992

Toward precision medicine in glioblastoma: the promise and the challenges

artículo científico

Tracking tumor growth rates in patients with malignant gliomas: a test of two algorithms.

artículo científico publicado en 2001

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report

artículo científico publicado en 2000

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

artículo científico publicado en 1999

Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy

artículo científico publicado en 2014

Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.

artículo científico publicado en 2014

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

artículo científico publicado en 2003

Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology ⬇️

artículo científico publicado en 2020

Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab.

artículo científico publicado en 2010

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

artículo científico publicado en 2010

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio

artículo científico publicado en 2016

Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line

artículo científico publicado en 2004

Using molecular information to guide brain tumor therapy

artículo científico publicado en 2006

Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

artículo científico publicado en 2018

Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry

artículo científico publicado en 2019

Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment

scientific article published on 24 April 2020

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

artículo científico publicado en 2018

Voxel-Wise and Patient-Wise Correlation of 18F-FDOPA PET, rCBV, and ADC in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes

artículo científico publicado en 2020

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

artículo científico

Will kinase inhibitors make it as glioblastoma drugs?

artículo científico publicado en 2012

mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc

scientific article published on 17 October 2013

mTOR signaling in glioblastoma: lessons learned from bench to bedside ⬇️

artículo científico publicado en 2010

mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.

artículo científico publicado en 2017

mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma

scientific article published on 11 November 2019

p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition

artículo científico publicado en 2004

pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma

scientific article published on 26 February 2019

pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI

artículo científico publicado en 2015

¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda